The purpose of the study is to evaluate the efficacy of stenting after dilation with or without paclitaxel-eluting balloon or atherectomy in patients with symptomatic peripheral artery disease.
The superficial femoral artery is a common place for arteriosclerosis in patients symptomatic for lower extremity vascular disease. Advances in percutaneous transluminal angioplasty (PTA) and stenting have provided new options for the treatment of the disease in this arterial segment. Despite the initial technical success rate of more than 95% the late clinical failure remains an important concern. Restenosis after PTA occurs in 40-60% within one year. Percutaneous removal of the obstructive material through atherectomy may reduce restenosis rate. So far, data in support of excisional atherectomy derive from registries. Another attempt to reduce restenosis is the use of paclitaxel eluting balloons (PEB). First clinical studies suggest that the use of PEBs during percutaneous treatment of femoropopliteal disease is associated with significant reductions in late lumen loss and target-lesion revascularization. There is no randomized comparison of this three different interventional strategies. Thus the aim of this study is to evaluate the efficacy of these strategies in terms or reduction of diameter stenosis at follow-up angiogram.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
150
Nitinol stent
Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
Atherectomy
Deutsches Herzzentrum
München, Germany
RECRUITINGI. Medizinische Klinik, Klinikum rechts der Isar
München, Germany
RECRUITINGPercentage diameter stenosis
Time frame: 6 months
All-cause mortality
Time frame: 6 and 24 months
Major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation or revascularization (PTA or bypass surgery)
Time frame: 6 months
Time to onset of any of MAPE.
Time frame: 3-24 months
Binary restenosis rate
Time frame: 6 months
Percentage diameter stenosis in duplex ultrasound
Time frame: 6 and 24 months
Change from baseline in functional status and health related quality of life (Walking Impairment Questionaire)
Time frame: 3 and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.